RSABE… [Regulatives / Guidelines]

posted by Loky do – Egypt, 2021-02-24 16:30 (712 d 23:15 ago) – Posting: # 22230
Views: 2,171

Hi Dear Helmut,

Many thanks for your reply :-D:-D

❝ Which book are you referring to?


❝ For the FDA you can apply RSABE for any PK metric (AUCs, partial AUCs, Cmax, :blahblah:) if its \(\small{s_{\textrm{wR}}\geq 0.294\;(CV_{\textrm{wR}}\geq\approx0.300469\ldots)}\)

❝ If \(\small{s_{\textrm{wR}}<0.294}\) you have to evaluate the respective PK metric for ABE.


I didn't find this statement in FDA guidance for bioequivalence studies just in progesterone guidance so, is it enough to refer to this guide while submitting the study to regulatory (as the intrasubject variability CV% equal 57%, partially replicate design), or is there another guide would support this way? please advice?

Thanks in advance

Complete thread:

UA Flag
Activity
 Admin contact
22,485 posts in 4,710 threads, 1,603 registered users;
23 visitors (0 registered, 23 guests [including 7 identified bots]).
Forum time: 15:45 CET (Europe/Vienna)

The difference between a surrogate and a true endpoint
is like the difference between a cheque and cash.
You can get the cheque earlier but then,
of course, it might bounce.    Stephen Senn

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5